## **A short synthesis of biologically active lignan analogues**

## **Stefan Kamlage,***a* **Michael Sefkow,***a* **Beatrice L. Pool-Zobel***b* **and Martin G. Peter\****a*

*a Institut für Organische Chemie und Strukturanalytik, Universität Potsdam, Karl-Liebknecht-Str. 24-25, D-14476 Golm, Germany. E-mail: peter@serv.chem.uni-potsdam.de*

*b Institut für Ernährungswissenschaften, Friedrich-Schiller-Universität Jena, Dornburger Str. 25, D-07743 Jena, Germany*

*Received (in Cambridge, UK) 20th October 2000, Accepted 12th January 2001 First published as an Advance Article on the web 31st January 2001*

## b**-Benzyl-**g**-butyrolactones were synthesized in four transition metal catalysed reactions from butynediol, and alkylated to afford new, biologically active lignan analogues.**

Lignans, dimers of phenylpropenes, are ubiquitous secondary plant metabolites.1 They exhibit notable biological activities, in particular antiviral,<sup>2</sup> cytotoxic<sup>3</sup> and canceroprotective<sup>4</sup> properties. Many lignan syntheses have been reported in the past.1,5 Two different strategies were most frequently followed for the synthesis of butyrolactone lignans **1**: 1. oxidative dimerization of *p*-hydroxycinnamic acids<sup>6</sup> and 2. alkylation of  $\beta$ -benzyl- $\gamma$ butyrolactones **2**.7 Following these routes, between 6 and 13 steps were necessary to obtain this class of lignans. We reported recently the Stille coupling8 of unsymmetrically protected 2-tributylstannylbuten-1,4-diols **3** with a variety of benzyl bromides.9 This coupling reaction was the key step for the preparation of lactones **2** from butynediol **4** (Scheme 1, Route A) but several protecting group manipulations were necessary and the overall yields were low (6–15%). Thus, a regioselective oxidation of 2-tributylstannylbut-2-en-1,4-diol (**5**) to lactone **6** was desirable for a short synthesis of lactone **2** (Scheme 1, Route B). Herein we report the synthesis of lactone **2** using only four transition metal catalysed reactions. Key step was the hitherto unknown, regioselective oxidation of diol **5** to lactone **6**.10

The palladium catalysed *cis*-selective addition of tributylstannane to butynediol **4** is well documented.11 The quality of diol **4** was crucial in this step. Purification of this compound prior to its use was necessary to obtain diol **5** in 92% yield (Scheme 2).

The hydroxy group at C(4) of diol **5** can be regioselectively protected using bulky silyl groups like the TBDMS group.12 We assumed that selective oxidation of this hydroxy group may occur if a sterically demanding oxidation reagent like TPAP13 in conjunction with NMO was employed. The selective oxidation of a primary hydroxy group in the presence of a secondary using this oxidation system was reported by Bloch and Brillet<sup>14</sup> but a regioselective oxidation of one of two primary hydroxy groups has not been published yet.

Treatment of diol **4** with 2.5 equivalents of NMO and 5 mol% TPAP at rt for 17 h afforded the lactones **6** and **7** in 15% yield and in a  $4:1$  ratio (Table 1, entry 1). The major compound isolated was furane **10** (30%) formed by elimination of water after initial oxidation to lactol **11** (Scheme 3).

Improved yields and selectivities were achieved when the initial temperature was below  $0^{\circ}$ C and the reaction mixture gradually warmed to rt over a period of 17 h (entries 2 and 3). Increasing the amount of TPAP and longer reaction times produced the lactones **6** and **7** in *ca.* 50% yield but the



**Scheme 1**



**Table 1** Reaction conditions for the TPAP-catalysed oxidation of diol **5** to lactones **6** and **7**



*a* Estimated by 1H NMR spectra of crude reaction products.



selectivity decreased with higher contents of the oxidation reagent (entries 4–6).

Lactones **6** and **7** were inseparable by flash chromatography and were therefore used as a mixture for the Stille coupling. This reaction was performed with benzyl bromides **8a**–**h** as described previously.<sup>9</sup> The  $\alpha$ ,  $\beta$ -unsaturated lactones **9a–h** were isolated as isomerically pure compounds (Scheme 2). Sweeney *et al.* described recently, that the reaction rates for the Stille coupling of lactones **6** and **7** with aryl halides are different.15 In analogy, only lactone **6** reacted with benzyl bromides **8a**–**h** to the coupling products **9a**–**h** (Table 2).

**Table 2** Benzyl bromides **8a**–**h** employed for the Stille coupling and yields of the reaction products **9a**–**h**

Entry	Residue(R)	<b>Bromide</b>	Lactone	Yield (%)
	4-Mesyl-3-methoxy	8а	9а	80
2	3,4,5-Trimethoxy	8b	9b	56
3	4-Methyl	8с	9с	76
$\overline{4}$	Н	8d	<b>9d</b>	70
5	4-Nitro	8e	9е	24
6	2,4,6-Trimethyl	8f	9f	77
7	3-Methoxy	8g	9g	59
8	3,4-Methylendioxy	8h	9h	45

Hydrogenation of lactones **9a**–**h** to lactones **2a**–**h** were achieved by means of 10% Pd on charcoal or Ra-Ni T4 (Table 3). The former catalyst, however, gave irreproducible results or no conversion. Additionally, high pressure (100 bar) and long reaction times ( > 24 h) were required. With Ra-Ni T4 as catalyst, complete conversion was found in all cases within 2 h at 0.1 bar positive pressure.

**Table 3** Hydrogenation of the unsaturated lactones **9a**–**h** using different catalysts

Entry	Unsat. lactone	Product	Catalyst	p/bar	t/h	Yield (% )
1	9a	2a	Pd/C	0.1	14	93
$\overline{2}$	9a	2a	Ra-Ni T4	0.1	$\overline{c}$	98
3	9b	2 <sub>b</sub>	Pd/C	0.1	14	$\overline{0}$
$\overline{4}$	9b	2 <sub>b</sub>	Ra-Ni T4	0.1	$\overline{c}$	70
5	9с	2c	Pd/C	0.1	24	98
6	9d	2d	Pd/C	50	48	97
7	9е	2e	Pd/C	0.1	14	$\theta$
8	9f	2f	Pd/C	0.1	14	$\theta$
9	9f	2f	Pd/C	100	72	88
10	9f	2f	Ra-Ni T4	0.1	$\overline{c}$	98
11	9g	2g	Pd/C	100	14	92
12	9h	2 <sub>h</sub>	$Pd(OH)_{2}$	100	16	$\theta$
13	9h	2 <sub>h</sub>	Ra-Ni T4	0.1	$\overline{2}$	70

Alkylation of lactones **2** with benzyl halides using LDA as base and HMPA as cosolvent provides lactone lignans **1**.1,7,16 We found that alkylation using LHMDS as base and DMPU17 as non-carcinogenic substitute for HMPA afforded lactones **1** in moderate yields (Scheme 4 and Table 4).

Bioassay of the synthetic lignan analogues using colon-tumor lines HT29 revealed that compound **1f** possesses high cytotoxic activity ( $IC_{50} = 40$  mM).<sup>18</sup>

We have shown that  $\beta$ -benzyl- $\gamma$ -butyrolactones 2 were effectively synthesised from butynediol **4** in four transition

**Scheme 4**

**Table 4** Alkylation of lactones **2d**,**f**–**h** to the symmetrically and unsymmetrically substituted lignan analogues **1**

Entry			Lactone Bromide Residue (R')	Lignan	Yield $(\%)^a$
	2d	8d	Н	1d	30
$\overline{2}$	2f	8f	2,4,6-Trimethyl	1f	43
3	2f	8h	3,4-Methylendioxy	1fb	25
$\overline{4}$	2g	8g	3-Methoxy	1g	18
.5	2 <sub>h</sub>	8h	3,4-Methylendioxy	1h	35
		<sup><i>a</i></sup> Reaction conditions not optimized.			

metal catalysed reactions. Alkylation of these compounds produced lignan analogues **1** with cytotoxic activities. An enantioselective route to this class of lignans is in progress.

This research was supported by the Deutsche Forschungsgemeinschaft (DFG) ( $\overline{INK}$  A26/1-1 and B26/1-1). MS acknowledges a habilitation grant from the DFG (Se875/1-1).

## **Notes and references**

- 1 D. C. Ayres and J. D. Loike, *Lignans: Chemical, Biological and Clinical Properties*, Cambridge University Press, Cambridge, 1990; R. S. Ward, *Nat. Prod. Rep.*, 1999, **16**, 75.
- 2 Recent reviews: J. L. Charlton, *J. Nat. Prod.*, 1998, **61**, 1447; E. Eich, *ACS Symp. Ser.*, 1998, **691**, 83; A. J. Vlietinck, T. De Bruyne, S. Apers and L. A. Pieters, *Planta Med.*, 1998, **64**, 97.
- 3 Recent reviews: S. E. Rickard and L. U. Thompson, *ACS Symp. Ser.*, 1997, **662**, 273; D. M. Tham, C. D. Gardner and W. L. Haskell, *J. Clin. Endocrinol. Metab.*, 1998, **83**, 2223; C. D. N. Humfrey, *Nat. Toxins*, 1998, **6**, 51; J. M. Cline and C. L. Hughes, Jr., *Cancer Treat. Res.*, 1998, **94**, 107; W. Mazur and H. Adlercreutz, *Pure Appl. Chem.*, 1998, **70**, 1759; S. Bingham, *Pure Appl. Chem.*, 1998, **70**, 1777.
- 4 S. R. Stitch, J. K. Toumba, M. B. Groen, C. W. Funke, J. Leemhuis, J. Vink and G. F. Woods, *Nature*, 1980, **287**, 738; K. D. R. Setchell, A. M. Lawson, F. L. Mitchell, H. Adlercreutz, D. N. Kirk and M. Axelson, *Nature*, 1980, **287**, 740; M. Axelson, J. Sjövall, B. E. Gustafsson and K. D. R. Setchell, *Nature*, 1982, **298**, 659; L. U. Thompson, P. Robb, M. Serraino and F. Cheung, *Nutr. Cancer*, 1991, **16**, 43.
- 5 R. S. Ward, *Chem. Soc. Rev.*, 1982, **11**, 75; R. S. Ward, *Tetrahedron*, 1990, **46**, 5029.
- 6 N. J. Cartwright and R. D. Haworth, *J. Chem. Soc.*, 1944, 535; K. Weinges and R. Spänig, in *Oxidative Coupling of Phenols*, ed. W. I. Taylor and A. R. Battersby, Marcel Dekker, New York, 1967; D. E. Bogucki and J. L. Charlton, 1997, **75**, 1793.
- 7 J. M. de L. Vanderlei, F. Coelho and W. P. Almeida, *Synth. Commun.*, 1998, **28**, 3047.
- 8 J. K. Stille, *Angew. Chem.*, 1986, **98**, 504; V. Farina, V. Krishnamurthy and W. J. Scott, *Org. React.*, 1997, **50**, 512.
- 9 S. Kamlage, M. Sefkow and M. G. Peter, *J. Org. Chem.*, 1999, **64**, 2938.
- 10 H. X. Zhang, F. Guibe and G. Balavoine, *J. Org. Chem.*, 1990, **55**, 1857.
- 11 A. G. M. Barrett, T. E. Barta and J. A. Flygare, *J. Org. Chem.*, 1989, **54**, 4246.
- 12 G. J. Hollingworth, G. Perkins and J. Sweeney, *J. Chem. Soc., Perkin Trans. 1*, 1996, 1913.
- 13 S. V. Ley, J. Norman, W. P. Griffith and S. P. Marsden, *Synthesis*, 1994, 639–666.
- 14 R. Bloch and C. Brillet, *Synlett*, 1991, 829.
- 15 R. Mabon, A. M. E. Richecœur and J. B. Sweeney, *J. Org. Chem.*, 1999, **64**, 328.
- 16 R. Chênevert, G. Mohammadi-Zirani, D. Caron and M. Dasser, *Can. J. Chem.*, 1999, **77**, 223.
- 17 T. Mukhopadhyay and D. Seebach, *Helv. Chim. Acta*, 1982, **65**, 385.
- 18 T. W. Becker, M. G. Peter and B. L. Pool-Zobel, in *Proceedings of the Food and Cancer Prevention III Meeting, Norwich, UK*, 1999, ed. I. T. Johnson and G. R. Fenwick, Special Publication No 255, Royal Society of Chemistry, Cambridge, UK, p. 151.